Mehrdad Ariani
Interventional Cardiology · Northridge, CANPI 1942496211
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Merck at 36.9% of the total. Reporting peaked in 2022 at $31,276 and has fallen 84.0% since, to $5,011 in 2025.
Across 1,184 payments — averaging $79.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$35K
- AstraZeneca$17K
- Medicure Pharma Inc.$7K
- Amgen$6K
- Abbott$6K
- Boston Scientific$5K
- plus $19K from 50 others
Across 801 payments — averaging $6205.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1M
- Astrazeneca UK Limited$997K
- Eli Lilly$781K
- CSL Behring$591K
- Novo Nordisk AS$412K
- Merck$265K
- plus $882K from 11 others
What the payments were for
- Consulting fees$7,1178%
- Speaking & faculty fees$49,49052%
- Travel & lodging$7,3288%
- Food & beverage$30,03232%
- Education$6431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$33,282
- FARXIGA$15,573
- Aggrastat (tirofiban HCl)$7,117
- Repatha$4,624
- VersaCross Access Solution$2,510
- AVEIR$1,207
- OPTIMIZER$924
- Impella$921
- Micra$318
- COREVALVE EVOLUT R$306
- Quadra Assura CRT Defibrillator$292
- ASSURITY$290
- WATCHMAN FLX$267
- Auryon Laser System 100-120 Vac$246
- XARELTO$245
- JARDIANCE$232
- Fortify Assura, Ellipse ICD$219
- CoreValve Evolut$194
- Barostim Neo System$193
- FFRangio$158
How this compares
$94,610 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 375 | $349,985 |
| EntrestoSacubitril/Valsartan | 310 | $276,875 |
| XareltoRivaroxaban | 264 | $221,689 |
| Repatha SureclickEvolocumab | 233 | $190,306 |
| OpsumitMacitentan | 11 | $141,540 |
| VerquvoVericiguat | 108 | $92,373 |
| MultaqDronedarone Hcl | 69 | $88,153 |
| FarxigaDapagliflozin Propanediol | 102 | $69,260 |
| OzempicSemaglutide | 51 | $55,946 |
| VascepaIcosapent Ethyl | 120 | $53,035 |
| JardianceEmpagliflozin | 52 | $46,354 |
| TrintellixVortioxetine Hydrobromide | 56 | $33,588 |
| BrilintaTicagrelor | 49 | $30,941 |
| MounjaroTirzepatide | 25 | $29,103 |
| CorlanorIvabradine Hcl | 34 | $24,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,081 | $349,985375 claims |
| NovartisEntresto | $1,599 | $276,875310 claims |
| Johnson & JohnsonXarelto | $2,090 | $221,689264 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $347 | $141,54011 claims |
| AstraZenecaFarxiga, Brilinta, Crestor | $17,238 | $105,638163 claims |
| MerckVerquvo | $34,928 | $92,373108 claims |
| Sanofi-aventis U.S. LLCMultaq, Plavix | $381 | $91,70980 claims |
| Novo NordiskOzempic, Rybelsus | $961 | $76,25667 claims |
| Boehringer IngelheimJardiance | $1,136 | $46,35452 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $382 | $33,58856 claims |
| Lilly USA, LLCMounjaro | $301 | $29,10325 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $19 | $28,30489 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Northridge
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.